IBIO Archives - Page 6 of 8

Markets

AGP starts iBio at buy; PT $2.55

Alliance Global Partners launched coverage of iBio (NYSE American:IBIO) with a “buy” rating and price target of $2.55. The stock closed at $1.61 on June 25 but has traded as high as $2.69 on June 26. Shares of iBio will...

June 26, 2020

Developments

Texas A&M video series features iBio COVID-19 vaccines

iBio’s (NYSE American:IBIO) two COVID-19 vaccine candidates were featured on the final episode of the video series, “COVID-19: The Texas A&M University System Responds.” “This is an important collaboration,” John...

June 26, 2020

Developments

iBio to be added to Russell 2000 and Russell 3000 indexes

iBio (NYSE AMERICAN:IBIO) will be added to the Russell 2000 and Russell 3000 indexes after markets open on June 29, as part of the Russell indexes annual reconstitution. In early trading on June 26, shares of iBio...

June 26, 2020

Developments

IBM Watson Health selects iBio to support COVID-19 vaccine candidates

IBM Watson Health selected iBio (NYSE American:IBIO) to receive 18 months use of the IBM clinical development (ICD) solution at no cost. IBM Watson Health recently began offering its clinical development solution to...

June 24, 2020

Developments

iBio initiates second COVID-19 vaccine program

iBio (NYSE AMERICAN:IBIO) initiated preclinical immunization studies for its second COVID-19 vaccine platform with the potential for rapid manufacturing scale-up at its FastPharming System. The new subunit vaccine, IBIO...

June 4, 2020

Developments

iBio sees 500 million COVID-19 vaccine dose capacity at its FastPharming facility

iBio (NYSE AMERICAN:IBIO) estimates that its FastPharming facility could manufacture some 500 million doses of COVID-19 vaccine annually. “If our own proprietary SARS-CoV-2 virus-like particle (VLP) program, IBIO-200...

April 27, 2020

Developments

iBio expands COVID-19 vaccine program to include Infectious Disease Research Institute

iBio (NYSE AMERICAN:IBIO) signed two master services agreements (MSAs) and a memorandum of understanding (MoU) with the Infectious Disease Research Institute to support iBio’s SARS-CoV-2 virus-like particle vaccine...

April 9, 2020

Feature

Amidst a global pandemic, two biotech companies offer innovative solutions

Since COVID-19 was first identified in China late last year, researchers have been working tirelessly to develop diagnostics, therapeutics and vaccines in an effort to prevent the spread of the SARS-CoV-2 virus. Many...

March 31, 2020

Developments

iBio supporting AzarGen’s development of plant-made rituximab

iBio (NYSE AMERICAN:IBIO) will manufacture and characterize additional supplies of plant-made rituximab for South Africa’s AzarGen, enabling preclinical studies to compare plant-made rituximab to the original molecule...

March 26, 2020

Developments

iBio begins immunization studies of COVID-19 vaccine candidates

iBio (NYSE AMERICAN:IBIO) commenced immunization studies for its SARS-CoV-2 virus-like particle (VLP) program, IBIO-200, at Texas A&M University System laboratories. The company used its plant-based FastPharming...

March 26, 2020

Tag - IBIO

AGP starts iBio at buy; PT $2.55

Texas A&M video series features iBio COVID-19 vaccines

iBio to be added to Russell 2000 and Russell 3000 indexes

IBM Watson Health selects iBio to support COVID-19 vaccine candidates

iBio initiates second COVID-19 vaccine program

iBio sees 500 million COVID-19 vaccine dose capacity at its FastPharming facility

iBio expands COVID-19 vaccine program to include Infectious Disease Research Institute

Amidst a global pandemic, two biotech companies offer innovative solutions

iBio supporting AzarGen’s development of plant-made rituximab

iBio begins immunization studies of COVID-19 vaccine candidates

General

More